This decision-analytic modeling study of simulated patients with biochemical recurrent prostate cancer estimated that upfront PSMA-PET may lead to 75 fewer deaths from prostate cancer, 988 more life-years, and 824 more quality-adjusted life-years per 1000 patients compared with conventional imaging. The gene discussed is FOLH1; the disease is prostate cancer.